Chad M. Robins Sells 211,160 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Co. (NASDAQ:ADPT) CEO Chad M. Robins sold 211,160 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $8.50, for a total transaction of $1,794,860.00. Following the sale, the chief executive officer now owns 2,576,701 shares in the company, valued at $21,901,958.50. The trade was a 7.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Adaptive Biotechnologies Trading Down 0.4 %

Shares of ADPT stock traded down $0.04 during trading hours on Tuesday, hitting $8.30. The company’s stock had a trading volume of 2,319,872 shares, compared to its average volume of 1,590,137. The business has a fifty day moving average of $7.05 and a 200-day moving average of $5.68. Adaptive Biotechnologies Co. has a twelve month low of $2.28 and a twelve month high of $8.95. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of -6.19 and a beta of 1.50.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its earnings results on Tuesday, February 11th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.04. Adaptive Biotechnologies had a negative return on equity of 62.06% and a negative net margin of 110.13%. During the same quarter in the previous year, the firm posted ($0.30) EPS. On average, equities analysts expect that Adaptive Biotechnologies Co. will post -1.08 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on ADPT shares. Piper Sandler boosted their price objective on shares of Adaptive Biotechnologies from $6.00 to $7.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. BTIG Research boosted their price target on Adaptive Biotechnologies from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. The Goldman Sachs Group raised their price objective on Adaptive Biotechnologies from $5.50 to $7.50 and gave the company a “neutral” rating in a research note on Tuesday, January 28th. Finally, Scotiabank boosted their target price on Adaptive Biotechnologies from $10.00 to $12.00 and gave the stock a “sector outperform” rating in a research report on Thursday, February 13th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Adaptive Biotechnologies currently has an average rating of “Moderate Buy” and a consensus price target of $8.30.

Institutional Trading of Adaptive Biotechnologies

Large investors have recently made changes to their positions in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Adaptive Biotechnologies in the 4th quarter valued at about $711,000. Voloridge Investment Management LLC acquired a new position in shares of Adaptive Biotechnologies in the fourth quarter valued at approximately $174,000. Soleus Capital Management L.P. lifted its stake in shares of Adaptive Biotechnologies by 168.1% during the fourth quarter. Soleus Capital Management L.P. now owns 2,983,142 shares of the company’s stock valued at $17,884,000 after buying an additional 1,870,393 shares during the period. Squarepoint Ops LLC boosted its position in Adaptive Biotechnologies by 265.3% during the fourth quarter. Squarepoint Ops LLC now owns 44,401 shares of the company’s stock worth $266,000 after acquiring an additional 32,247 shares during the last quarter. Finally, Two Sigma Advisers LP grew its stake in Adaptive Biotechnologies by 396.2% in the 4th quarter. Two Sigma Advisers LP now owns 51,600 shares of the company’s stock worth $309,000 after acquiring an additional 41,200 shares during the period. Institutional investors and hedge funds own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.